Menu
Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 7
Ustekinumab for the treatment of psoriatic arthritis: an update
Authors Davari P, Leo M, Kamangar F, Fazel N
Received 14 May 2014
Accepted for publication 6 June 2014
Published 2 September 2014 Volume 2014:7 Pages 243—249
DOI https://doi.org/10.2147/CCID.S50003
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Parastoo Davari, Michael S Leo, Faranak Kamangar, Nasim Fazel
Department of Dermatology, University of California, Davis, CA, USA
Abstract: Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis.
Keywords: psoriatic arthritis, psoriasis, ustekinumab
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.